SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Biotechnology
$21.01
+0.86 (+4.27%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 24.04M | 43.44M | 335.52M | 332.47M | 314.66M |
| Net Income | -323,566,532 | -526,219,513 | -86,065,429 | -96,723,913 | -70,006,891 |
| EPS | — | — | — | — | — |
| Profit Margin | -1,346.1% | -1,278.8% | -25.7% | -29.1% | -22.3% |
| Rev Growth | -44.7% | -44.7% | -8.5% | -3.0% | +7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 496.68M | 496.68M | 503.40M | 451.31M | 465.02M |
| Total Equity | 416.36M | 416.36M | 836.92M | 843.32M | 828.46M |
| D/E Ratio | 1.19 | 1.19 | 0.60 | 0.54 | 0.56 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -345,043,187 | -592,322,059 | -127,710,433 | -125,567,751 | -117,470,983 |
| Free Cash Flow | — | — | -48,776,040 | -63,645,585 | -69,021,041 |